Skip to content

Effects of Duloxetine in treatment of patients with resistant obsession

Comparing Duloxetine with Sertraline as augmentation factor in resistant obsessive compulsive disorder (OCD)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016020121745N1
Enrollment
70
Registered
2016-04-10
Start date
2016-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: It is a randomized study that is done during 6 weeks. The subjects are pateints with OCD who have not responded to selective seretonin reuptake inhibitors (SSRI). Inpateint and outpate
Treatment - Drugs
It is a randomized study that is done during 6 weeks. The subjects are pateints with OCD who have not responded to selective seretonin reuptake inhibitors (SSRI). Inpateint and outpateint of Shiraz Un

Sponsors

Vice chancellor of research Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion crieteria: Patients with OCD that diagnosed with interview by psychiatrist according to DSMIV TR; Peaple that did not response to optimal and constant dose of selective seretonin reuptake inhibitors; Yale-Brown-obsessive-compulsive scale equal or more than 18; informed consent of patients or his/her protector. Exclusion criteria: other psychiatric disorder diagnosis; major medicall illness like hypertension. diabetes, cardiovascular disease, renal disease, gastrointestinal disease; pregnancy, substance abuse, previously used of sertraline; patients younger than 18 years and older than 65 years old

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of obsession. Timepoint: 0th week and sixth week. Method of measurement: Y-BOCS at 0 and 6th week. CGI test at 6th week.

Secondary

MeasureTime frame
Not used. Timepoint: not used. Method of measurement: not used.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSanaz Boostani

Shiraz University of Medical Sciences

Sanaz_boostani_63@yahoo.com; Sanazboostani1363@gmail.com+98 71 3627 9319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026